GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.

@article{Trujillo2014GLP1RA,
  title={GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents.},
  author={Jennifer M Trujillo and Wesley Nuffer},
  journal={Pharmacotherapy},
  year={2014},
  volume={34 11},
  pages={
          1174-86
        }
}
More than 26 million people in the United States have type 2 diabetes mellitus (T2D). Many treatment options exist, but achieving long-term glycemic control in patients with T2D remains challenging. The glucagon-like peptide-1 receptor agonists (GLP-1 RAs) offer a treatment option that improves glycemic control and reduces weight, with a low risk of hypoglycemia. They have emerged as attractive options for the treatment of T2D, and significant advances and developments continue to be published… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 28 CITATIONS

GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women.

  • The Journal of clinical endocrinology and metabolism
  • 2015
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

Liraglutide as additional treatment to insulin in patients with type 1 diabetes mellitus: a randomized controlled trial. Diabetes 2014;63(Suppl 1):A250

ND Kuhadiya, S Dhindsa, A Makdissi
  • 2014
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Liraglutide as additional treatment for type 1 diabetes.

  • European journal of endocrinology
  • 2011
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

  • Nature Reviews Endocrinology
  • 2012
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL